Immedica Pharma was established in 2018 by Impilo and a management team with previous experience in launching and commercialising orphan drugs across Europe. The business has developed drugs primarily within haematology and oncology as well as genetic and metabolic diseases for rare conditions with high unmet medical need, with revenues of €100m and annual growth of more than 50%, according to the press release.
KKR is investing in Immedica through its KKR Health Care Strategic Growth Fund II, a $4bn fund focused on high-growth healthcare companies. KKR has invested approximately $20bn in the healthcare sector since 2004.
Source: Private Equity Wire
Can’t stop reading? Read more
Clearlake Capital strengthens executive bench as it scales global investment platform
Clearlake Capital strengthens executive bench as it scales global investment platform Clearlake...
Croatia’s Prosperus Growth acquires Neos to anchor IT platform strategy
Croatia’s Prosperus Growth acquires Neos to anchor IT platform strategy Croatian private equity...
Alter Capital takes control of Wifit Gyms to accelerate Iberian expansion
Alter Capital takes control of Wifit Gyms to accelerate Iberian expansion Alter Capital Desarrollo...